9.1.4. Drugs used in platelet disorders
Restrictions:
Restricted to specialist use only for the reduction of elevated platelet counts in at-risk patients with essential thrombocythaemia who are intolerant of their current therapy or whose elevated platelet counts are not reduced to an acceptable level by their current therapy.
Restrictions:
Restricted to specialist use for the following indications:
- The treatment of severe thrombocytopenia in adults with chronic liver disease who are scheduled to undergo an invasive procedure
- The treatment of primary chronic thrombocytopenia (ITP) refractory to other treatments (e.g. corticosteroids or immunoglobulins) where patients have severe symptomatic ITP or a high risk of bleeding in accordance with local protocol (in development).
Restrictions:
The treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), in conjunction with plasma exchange and immunosuppression is restricted to specialist use in accordance with regional protocol.
Restrictions:
Restricted to use as detailed in Prescribing Notes section below.
Prescribing Notes:
Formulary indications:
- Adult chronic immune (idiopathic) thrombocytopenic purpura (ITP) is restricted to specialist use in accordance with local protocol.
- Treatment of thrombocytopenia in adults with chronic hepatitis C is restricted to specialist use.
Non-formulary indications:
- Treatment in adult patients with acquired severe aplastic anaemia (SAA) who were either refractory to prior immunosuppressive therapy or heavily pre-treated and are unsuitable for haematopoietic stem cell transplantation.
Restrictions:
Treatment of chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments is restricted to specialist use.
Restrictions:
Restricted to specialist use for the treatment of severe thrombocytopenia in adults patients with chronic liver disease undergoing invasive procedures.
Restrictions:
Restricted to specialist use only. Restricted to use in patients with severe symptomatic immune (idiopathic) thrombocytopenia purpura (ITP) or patients with a high risk of bleeding.


